FDA Approves Ultomiris to Help Lower Protein Levels in Kidney Disease

The FDA has approved Ultomiris (ravulizumab) for adults with primary immunoglobulin A nephropathy (IgAN), a rare kidney disease, to reduce protein levels in urine and slow kidney damage progression. The drug carries infection risks and is available through a special safety program.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 22 Oct 2026 and 2 Nov 2026.